Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Cerebral Vasoconstriction and Stroke After Use of Serotonergic Drugs
Neurol 58:130-133, Singhal,A.B.,et al, 2002
Burning Mouth Syndrome
Am Fam Physician 65:615-620, Gruska,M.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Dysgeusia in Epileptic Patients Treated with Lamotrigine: Report of Three Cases
Neurol 57:1521, Avoni,P.,et al, 2001
Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke
Arch Neurol 58:2009-2013, Grotta,J.C.,et al, 2001
Acute Stroke Care in Non-urban Emergency Departments
Neurol 57:2006-2012, Burgin,W.S.,et al, 2001
Treatment of Acute Basilar Artery Thrombosis With a Combination of Systemic Alteplase and Tirofiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Inhibitor: Report of Four Cases
Radiology 221:795-801, Junghans,U.,et al, 2001
Safety of Intra-Arterial Thrombolysis in the Postoperative Period
Stroke 32:1365-1369, Chalela,J.A.,et al, 2001
Thrombolysis of Extracranial and Intracranial Arteries After IV Abciximab
Neurol 56:1582-1584, Houdart,E.,et al, 2001
Rescue Treatment with Abciximab in Acute Ischemic Stroke
Neurol 56:1585-1587, Lee,K.Y.,et al, 2001
Nonrandomized Comparison of Local Urokinase Thrombolysis Versus Systemic Heparin Anticoagulation for Superior Sagittal Sinus Thrombosis
Stroke 32:2310-2317, Wassay,M.,et al, 2001
Cerebral Hemorrhage After Intra-arterial Thrombolysis for Ischemic Stroke
Neurol 57:1603-1610, Kase,C.S.,et al, 2001
Risk Factors for Sever Hemorrhagic Transformation in Ischemic Stroke Patients Treated with Recombinant Tissue Plasminogen Activator
Stroke 32:438-441, Larrue,V.,et al, 2001
Clinicopath Conf, Strychnine Poisoning, Case 12-2001
NEJM 344:1232-1239, , 2001
Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated with Symptomatic Intracerebral Hemorrhage
Stroke 32:12-16, Lopez-Yunez,A.M.,et al, 2001
Rapid Initiation of Gabapentin, A Randomized, Controlled Trial
Neurol 56:743-748, Fisher,R.S.,et al, 2001
Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001
Positive Response to Immunommodulatory Therapy in an Adult Patient with Rasmussen's Encephalitis
Neurol 56:248-250, Villani,F.,et al, 2001
Epilepsy
NEJM 344:1145-1151, Browne,T.R. & Holmes,G.L., 2001
Uveal Effusion and Secondary Angle-Closure Glaucoma Associated with Topiramate Use
Arch Ophthalmol 119:1210-1211, Sankar,P.S., 2001
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids
NEJM 343:1833-1838,1886, Haller,C.A. & Benowitz,N.L., 2000
Phenylpropanolamine and the Risk of Hemorrhagic Stroke
NEJM 343:1826-1832,1886, Kernan,W.N.,et al, 2000
Cerebral Venous Thrombosis: Anticoagulants or Thrombolyic Therapy?
JNNP 69:427-430, Benamer,H.T.S. & Bone,I., 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Treatment of Acute Ischemic Stroke
NEJM 343:710-722, Brott, T. & Bogousslavsky, J., 2000
Acute Neurologic Decompensation in an Infant With Cobalamin Deficiency Exposed to Nitrous Oxide
J Pediatr 137:427-428, Felmet,K. et al, 2000
Intravenous Valproate is Well Tolerated in Unstable Patients with Status Epilepticus
Neurol 55:722-724, Sinha,S. & Naritoku,D.K., 2000
Orolingual Angioneurotic Edema Following Therapy of Acute Ischemic Stroke with Alteplase
Neurol 55:599-600, Rudolf,J. et al, 2000
Intracranial Hemorrhage Associated With Thrombolytic Therapy for Eldery Patients With Acute Myocardial Infarction
Stroke 31:1802-1811, Brass,L.M. et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Intravenous Valproic Acid for Myoclonic Status Epilepticus
Neurol 54:1201, Sheth,R.D. & Gidal,B.E., 2000
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke
JAMA 283:1145-1150,1189, Albers,G.W.,et al, 2000
Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke
JAMA 283:1151-1158,1189, Katzan,I.L.,et al, 2000
Intravenous Valproate in Pediatric Epilepsy Patients with Refractory Status Epilepticus
Neurol 54:2188-2189, Uberall,M.A.,et al, 2000
Nitrous Oxide Anesthesia-Associated Myelopathy
ArchNeurol 57:380-382, Marie,R.,et al, 2000
Superior Sagittal Sinus Thrombosis Due to Lithium:Local Urokinase Thrombolysis Treatment
Neurol 54:532-533, Wasay,M.,et al, 2000
Treating Acute Stroke Patients with Intravenous tPA, The OSF Stroke Network Experience
Stroke 31:77-81, Wang,D.Z.,et al, 2000
Cerebral Venous Thrombosis Associated with Epoetin Alfa Therapy
Arch Neurol 57:260-262, Finelli,P.F.&Carley,M.D., 2000
Weak and Numb Feet in a Man with Knobby Hands, Report of a Case
Arch Neurol 57:271, Kaplan,P.W.,et al, 2000
Gabapentin-Induced Anorgasmia
Neurol 53:2209, Clark,J.D.&Elliott,J., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset, The ATLANTIS Study:A Randomized Controlled Trial
JAMA 282:2019-2026, Clark,W.M.,et al, 1999
Suppression of Pendular Nystagmus by Smoking Cannabis in a Patient with Multiple Sclerosis
Neurol 53:2209-2210, Schon,F.,et al, 1999
Pompholyx (Vesicular Eczema) After IV Immunoglobulin Therapy for Neurologic Disease
Neurol 53:1154-1155, Iannaccone,S.,et al, 1999
Spastic Paraparesis after Anaesthesia
Lancet 353:554, Lee,P.,et al, 1999
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999